Skip to main content

Advertisement

Fig. 3 | BMC Cancer

Fig. 3

From: Platinum (IV)-fatty acid conjugates overcome inherently and acquired Cisplatin resistant cancer cell lines: an in-vitro study

Fig. 3

PARP cleavage induced by Cisplatin (IV) prodrugs. A2780cisR (a, c) and A2780 (b) cells were treated with Cisplatin, RJY6 and RJY13 for 30 h as described in Materials and Methods. Quantitative evaluation of cleaved PARP in A2780cisR cells exposed to Cisplatin, RJY6 and RJY13 at (1, 5 and 25 microM) (c) were performed as described in Materials and Methods. P values; * P < 0.05 and **P < 0.005

Back to article page